Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

sanofi pasteur europe, france 14 espace henry vallee, 69007 lyon +33 437 28 40 00 - purified tetanus toxoid; purified diphteria toxoid; purified pertussis toxoid (pt xd); filamentous haemagglutinin (fha); inactivated poliovirus vacc type i; inactivated poliovirus vacc type ii; inactivated poliovirus vacc type iii; haemophilus type b polysac. conjugated to tetanus protein - inj.susp (ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ); pd.inj.sus (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - 0,5ml (1dose) - purified tetanus toxoid 40iu; purified diphteria toxoid 20iu; purified pertussis toxoid (pt xd) 25mcg; filamentous haemagglutinin (fha) 25mcg; inactivated poliovirus vacc type i 29u; inactivated poliovirus vacc type ii 7u; inactivated poliovirus vacc type iii 26u; haemophilus type b polysac. conjugated to tetanus protein 10mcg - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

glaxosmithkline ΜΟΝΟΠΡΟΣΩΠΗ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΚΑΙ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ Δ.Τ. glaxosmithkline ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.Β.Ε. Λεωφ. Κηφισίας 266,, 152 32 152 32, Χαλάνδρι 210-6882100 - pertussis toxoid (pt); filamentous haemagglutinin (fha); pertactin (69 kda outer membrane protein-69k); diphtheria toxoid, adsorbed; tetanus toxoid; inactivated poliovirus vacc type i; inactivated poliovirus vacc type ii; inactivated poliovirus vacc type iii; conjugate of haemophilus influenzae type b capsular polysaccharide(prp) and tetanus toxoid - pd.su.in.s (ΚΟΝΙΣ ΚΑΙ ΕΝΑΙΩΡΗΜΑ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - pertussis toxoid (pt) 25mcg; filamentous haemagglutinin (fha) 25mcg; pertactin (69 kda outer membrane protein-69k) 8mcg; diphtheria toxoid, adsorbed 0 => 30iu; tetanus toxoid 0 => 40iu; inactivated poliovirus vacc type i 40du; inactivated poliovirus vacc type ii 8du; inactivated poliovirus vacc type iii 32du; conjugate of haemophilus influenzae type b capsular polysaccharide(prp) and tetanus toxoid 10mcg - hemophilus influenzae b, purified antigen conjugated; diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - Εμβόλια - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - (αιμοσυγκολλητίνη και νευραμινιδάση) του στελέχους Α / Βιετνάμ / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - Εμβόλια - Ενεργός ανοσοποίηση έναντι του υποτύπου h5n1 του ιού της γρίπης Α. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - Γρίπη, Ανθρώπινα - γρίπης, αδρανοποιημένο, split ιό ή αντιγόνο επιφανείας - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra πρέπει να χρησιμοποιείται σύμφωνα με τις επίσημες συστάσεις.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΠΑΣΤΕΡ Βασ.Σοφίας 127,, 115 21 115 21, Αθήνα 6462281, 6430044 - inactivated poliovirus vacc type i; inactivated poliovirus vacc type ii; inactivated poliovirus vacc type iii - inj.susp (ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - 0,5 ml/do - inactivated poliovirus vacc type i 0do; inactivated poliovirus vacc type ii 0do; inactivated poliovirus vacc type iii 0do - poliomyelitis, trivalent, inactivated, whole virus

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

sanofi pasteur. (0000010487) 14 espace henry vallee, lyon, 69007 - hepatitis a virus (gbm strain) inactivated - suspension for injection in pre-filled syringe - 160 antigen units/0.5ml - hepatitis a virus (gbm strain) inactivated (8000003025) 160u - hepatitis a, inactivated, whole virus

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - Γρίπη, Ανθρώπινα - Εμβόλια - Προφύλαξη από τη γρίπη σε ηλικιωμένους (65 ετών και άνω). fluad tetra πρέπει να χρησιμοποιείται σύμφωνα με τις επίσημες συστάσεις.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - Χοίροι - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - Εμβόλια - active immunisation against h5 subtype of influenza a virus.